Skip to main content
Novo NordiskIn development

Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval

Source: Autobound Signal API · 94 signals tracked for Novo Nordisk · updated

Get Novo Nordisk's live signals in Claude or ChatGPT, or by API

AskWhat changed at Novo Nordisk this week? Use Autobound signals for novonordisk.com.

What happened

Novo Nordisk submitted applications to the FDA and EMA seeking approval for etavopivat to treat sickle cell disease.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 13, 2026 /PRNewswire/ -- Novo Nordisk today announced the submissions of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat, an investigational, once-daily, orally available, selective activator of pyruvate kinase red blood cell isozyme (PKR), for the treatment of adolescents and adults (aged 12 years and older) living with sickle cell disease (SCD). If approved, etavopivat could offer a new approach to treating SCD as a disease-modifying therapy. The FDA has previously granted etavopivat Fast Track, Rare Pediatric Disease and Orphan Drug designations and is expected to take action on the NDA in 2027. Etavopivat was also granted Orphan Drug designation by the European Commission who is expected to take action on the MAA in 2027. A MAA is the formal application for seeking approval to market a medicine in the European Union (EU). "For people living with sickle cell disease, severe vaso-occlusive crises and other symptoms can have a profound impact on everyday life, and treatment options remain limited," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. "If approved, we are hopeful that etavopivat can provide a new disease-modifying...

Keep reading with a free account

The rest of this article, and every signal for Novo Nordisk, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
etavopivat
Takes effect
Nov 13, 2026
Location
Plainsboro, New Jersey, United States

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical
  • future tech
  • general technology

Extraction

Confidence
95%
Detected
Nov 13, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novo Nordisk and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novo Nordisk this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/baa0a712-6b86-ef4d-9f84-db4f10ffee03 returns this record as JSON. POST /v1/companies/enrich returns every signal for novonordisk.com.

{
  "signal_id": "baa0a712-6b86-ef4d-9f84-db4f10ffee03",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-13T11:00:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/novo-submits-etavopivat-an-investigational-once-daily-therapy-for-adolescents-and-adults-living-with-sickle-cell-disease-to-the-fda-and-ema-for-approval-302938346.html",
    "title": "Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval",
    "excerpt": "PLAINSBORO, N.J. and BAGSVÆRD, Denmark , Nov. 13, 2026 /PRNewswire/ -- Novo Nordisk today announced the submissions of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat, an investigational, once-daily, orally available, selective activator of pyruvate kinase red blood cell isozyme (PKR), for the treatment of adolescents and adults (aged 12 years and older) living with sickle cell disease (SCD). If approved, etavopivat could offer a new approach to treating SCD as a disease-modifying therapy. The FDA has previously granted etavopivat Fast Track, Rare Pediatric Disease and Orphan Drug designations and is expected to take action on the NDA in 2027. Etavopivat was also granted Orphan Drug designation by the European Commission who is expected to take action on the MAA in 2027. A MAA is the formal application for seeking approval to market a medicine in the European Union (EU). \"For people living with sickle cell disease, severe vaso-occlusive crises and other symptoms can have a profound impact on everyday life, and treatment options remain limited,\" said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. \"If approved, we are hopeful that etavopivat can provide a new disease-modifying treatment...",
    "product": "etavopivat",
    "summary": "Novo Nordisk submitted applications to the FDA and EMA seeking approval for etavopivat to treat sickle cell disease.",
    "location": "Plainsboro, New Jersey, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS1989915/Novo-Logo.jpg?id=OA3071262&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "etavopivat",
      "full_text": "etavopivat, an investigational, once-daily, orally available, selective activator of pyruvate kinase red blood cell isozyme (PKR)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "future_tech",
      "general_technology"
    ],
    "published_at": "2026-11-13T11:00:00Z",
    "location_data": [
      {
        "city": "Plainsboro",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-13",
    "article_sentence": "Novo Nordisk today announced the submissions of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etavopivat, an investigational, once-daily, orally available, selective activator of pyruvate kinase red blood cell isozyme (PKR), for the treatment of adolescents and adults (aged 12 years and older) living with sickle cell disease (SCD)."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.